Skip to content

Study on the microecological changes of stomach and duodenum in patients with nonalcoholic fatty liver disease

Study on the microecological changes of stomach and duodenum in patients with nonalcoholic fatty liver disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100051849
Enrollment
Unknown
Registered
2021-10-07
Start date
2021-10-15
Completion date
Unknown
Last updated
2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty liver disease (NAFLD)

Interventions

NAFLD group:gastroscopy
Healthy control group:gastroscopy

Sponsors

The First Affiliated Hospital, Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. NAFLD group: (1) Aged 18-75 years; (2) Histology or imaging studies suggest ''fatty liver'', without excessive alcohol consumption (men > 30g/day; women > 20g/day), viral hepatitis, autoimmune liver disease, drug-induced liver disease, hepatolenticular degeneration, etc. ; (3) No organic gastrointestinal lesions, such as inflammation, ulcers, tumors, etc. (including esophagitis, gastritis, duodenitis, peptic ulcer, celiac disease, inflammatory bowel disease, etc.); (4) Not taking antibiotics, probiotics, prebiotics, synbiotics, non-steroidal anti-inflammatory drugs (aspirin), etc. in the past month. 2. Healthy control group: (1) Aged 18-75 years; (2) Imaging indicates no hepatic steatosis; (3) No organic gastrointestinal lesions, such as inflammation, ulcers, tumors, etc. (including esophagitis, gastritis, duodenitis, peptic ulcer, celiac disease, inflammatory bowel disease, etc.); (4) Not taking antibiotics, probiotics, prebiotics, synbiotics, non-steroidal anti-inflammatory drugs (aspirin), etc. in the past month.

Exclusion criteria

Exclusion criteria: 1. History of tumor within five years; 2. Coagulation disorders, or taking anticoagulant drugs within one month.

Design outcomes

Primary

MeasureTime frame
Duodenal mucosal microbiome;Gastric mucosal microbiome;

Secondary

MeasureTime frame
Blood routine;Blood biochemical indicators;Body mass index;

Countries

China

Contacts

Public ContactJi Feng

The First Affiliated Hospital, Zhejiang University School of Medicine

jifeng@zju.edu.cn+86 571 87236862

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026